 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
June 28, 2012
Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Somagenics Holds Back on HCV Clinical Trial Amid Advances by Other Drugmakers
November 29, 2012 / Gene Silencing News - UniQure, Collaborators Secure $3.2M Eurostar Grant for Huntington’s Disease Effort
May 23, 2013 / Gene Silencing News - Tools & Techniques: TALENs for miRNA Manipulation; CLASH for miRNA-Target Analysis; and More
May 23, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Novartis, Tekmira, and More
May 23, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Santaris, Nitto Denko, BASF, and More
May 16, 2013 / Gene Silencing News